Illumina, Inc.
Illumina Announces Spin-Off of GRAIL and Associated Costs
Summary
Illumina, Inc. announced that its board of directors has approved the spin-off of GRAIL, involving the distribution of GRAIL shares to Illumina stockholders. The company estimates incurring approximately $35 - $50 million in charges related to this spin-off, primarily for legal and advisory fees, expected to be recognized by the third quarter of 2024. The distribution is set to occur on June 24, 2024, with GRAIL shares trading from June 25, 2024 under the symbol 'GRAL.'
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement